MiNK Therapeutics Inc. (INKT)

NasdaqCM: INKT · 실시간 가격 · USD

12.20

+0.58 (4.99%)

종가 기준: Aug 28, 2026, 8:00 PM

11.29

-1.17%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

4.99% (1D)

데이터 없음

매수호가	8.67
시가총액	58.32M
매출 (ttm)	n/a
순이익 (ttm)	-11.36M
	n/a
	-2.37
	n/a
	-4.32
P/B (ttm)	-4.15
P/S (ttm)	n/a
실적 발표일	n/a

매도호가	15.15
거래량	11,763
평균 거래량 (20일)	22,156
시가	11.64
전일 종가	11.62
일중 범위	11.22 - 12.20
52주 범위	8.48 - 16.98
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

INKT 소개

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the com...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 15, 2021

직원 수 15

상장 거래소 NasdaqCM

티커 INKT

웹사이트 https://minktherapeutics.com

전체 기업 정보

재무 실적

2025년 MiNK Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -12.49M로, 15.85% 증가했습니다.

재무제표

뉴스

2주 전 · Motley Fool

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript

Net loss narrowed to $3.1 million as Phase 2 trial for agenT-797 advances in Ukraine.

2주 전 · Moby

MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary

Moby summary of MiNK Therapeutics, Inc.'s Q2 2026 earnings call

2주 전 · GuruFocus.com

MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ...

MiNK Therapeutics reports encouraging initial data from its ARDS study, narrows net loss, and expands international access programs despite a tight cash position.

2주 전 · MarketBeat

MiNK Therapeutics Q2 Earnings Call Highlights

MiNK Therapeutics (NASDAQ:INKT) said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and ac...

1개월 전 · Zacks

Here's Why You Should Add INKT Stock to Your Portfolio Now

MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.

2 페이지 중 1

MiNK Therapeutics Inc. (INKT)

INKT 소개

재무 실적

어닝 서프라이즈

주가가 움직인 이유